52791-05-6

Basic information

• Product Name: 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE
• Synonyms: 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE;4-CHLORO-7,8-DIHYDRO[1,4]DIOXINO[2,3-G]QUINAZOLINE
• CAS NO: 52791-05-6
• Molecular Formula: C₁₀H₇ClN₂O₂
• Molecular Weight: 222.62778
• Mol File: 52791-05-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 375.4 °C at 760 mmHg
• Flash Point: 180.8 °C
• Appearance: /
• Density: 1.475 g/cm³
• Vapor Pressure: 1.69E-05mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE(52791-05-6)
• EPA Substance Registry System: 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE(52791-05-6)

Safety Data

• Hazardous Substances Data: 52791-05-6(Hazardous Substances Data)

Usage

General Description

4-Chloro-6,7-dimethylenedioxyquinazoline is a chemical compound that belongs to the quinazoline family. It is a chlorinated derivative of 6,7-dimethylenedioxyquinazoline and is often used in pharmaceutical research as a building block for the synthesis of novel drugs and medicinal compounds. The chloro group on the quinazoline ring provides unique reactivity and can be utilized for various chemical transformations to introduce different functional groups onto the quinazoline scaffold. 4-CHLORO-6,7-DIMETHYLENEDIOXYQUINAZOLINE has potential applications in the development of new drugs for the treatment of various diseases and conditions. Its chemical structure and reactivity make it a valuable intermediate for the synthesis of biologically active compounds.

InChI:InChI=1/C10H7ClN2O2/c11-10-6-3-8-9(15-2-1-14-8)4-7(6)12-5-13-10/h3-5H,1-2H2

Upstream product

• 1145671-34-6 4-chloroquinazoline-6,7-diyl bis(2,2-dimethylpropanoate) 
• 1174662-16-8 [7-(2,2-dimethylpropanoyloxy)-4-oxo-3H-quinazolin-6-yl] 2,2-dimethylpropanoate 
• 16064-15-6 6,7-dihydroxyquinazolin-4(3H)-one 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 1145671-36-8 4-chloro-6,7-dihydroxyquinazoline 
• 107-04-0 1-Bromo-2-chloroethane 
• 1207868-16-3 7,8-dihydro[1,4]dioxino[2,3-g]quinazoline 
• 22013-33-8 6-amino-3,4-benzodioxane 
• 99358-09-5 7-amino-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylic acid 
• 52791-04-5 3,4,7,8-tetrahydro[1,4]dioxino[2,3-g]quinazolin-4-one 

Downstream Products

• 1348397-98-7 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(3'-chloro-4'-fluorophenyl)amine hydrochloride 
• 1349202-84-1 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(4'-bromo-2'-fluorophenyl)amine hydrochloride 
• 1347999-78-3 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(3'-trifluoromethylphenyl)amine hydrochloride 
• 1350078-21-5 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(3'-methylphenyl)amine hydrochloride 
• 1348864-99-2 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(3'-bromophenyl)amine hydrochloride 
• 1456819-61-6 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(3'-methansulfonamidopheyl)amine hydrochloride 
• 1401243-69-3 (7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)-(biphenyl-3'-yl)amine hydrochloride 

Relevant articles and documents

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 INHIBITORS,COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of Formula (I), methods of using the compounds as ENPP1 inhibitors, and pharmaceutical compositions comprising such compounds.The compounds are useful in treating cancers and infectious diseases.

COMPOSITIONS AND METHODS FOR TREATING CANCER

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties

In this work the synthesis and the biological evaluation of some novel anilinoquinazoline derivatives carrying modifications in the quinazoline scaffold and in the aniline moiety were reported. Preliminary cytotoxicity studies identified three derivatives